Company Encyclopedia
View More
name
Pulse Biosciences
PLSE.US
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cycle; and The CellFX Consol, a tunable, software-enabled, and console-based platform designed to accommodate the clinical workflow preferred by physicians. The company was formerly known as Electroblate, Inc.
1.407 T
PLSE.USMarket value -Rank by Market Cap -/-

Financial Score

05/12/2025 Update
D
Health Care EquipmentIndustry
Industry Ranking121/171
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreE
    • ROE-86.99%E
    • Profit Margin-86898.84%E
    • Gross Margin-224.42%E
  • Growth ScoreC
    • Revenue YoY0.00%C
    • Net Profit YoY-61.99%D
    • Total Assets YoY16.89%A
    • Net Assets YoY17.14%A
  • Cash ScoreC
    • Cash Flow Margin-0.12%D
    • OCF YoY0.00%C
  • Operating ScoreE
    • Turnover0E
  • Debt ScoreA
    • Gearing Ratio14.78%A

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Pulse Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

    Pulse Biosciences Inc :PULSE BIOSCIENCES ANNOUNCES INDUCEMENT GRANTS UNDER NASDAQ LISTING RULE 5635(C)(4)

    Reuters·
    US
    PLSE
    0.00%
    Reuters·
    US
    PLSE
    0.00%

    Pulse Biosciences Grants Stock Options to New Employees Under Inducement Plan

    Pulse Biosciences Inc. has granted inducement stock options to three new employees, totaling 13,450 shares, under its 2017 Inducement Equity Incentive Plan. The options have an exercise price of $13.58 per share, matching the closing price on November 18, 2025, and will vest over four years. This announcement was made via Business Wire on November 21, 2025.

    Reuters·
    US
    PLSE
    0.00%
    Reuters·
    US
    PLSE
    0.00%

    Pulse Biosciences (PLSE): Assessing Valuation Following Modest Share Rebound and Recent Slowdown

    Pulse Biosciences (PLSE) shares have slightly rebounded, gaining nearly 2% after recent losses. Despite a three-year total shareholder return of 650%, recent momentum has slowed due to investor concerns about new risks and growth ambitions. The stock trades at a price-to-book ratio of 10.5x, significantly higher than the industry average of 2.5x, suggesting overvaluation. The company remains unprofitable with minimal revenue, raising questions about whether the current valuation is justified.

    Simplywall·
    US
    PLSE
    0.00%
    Simplywall·
    US
    PLSE
    0.00%

    Pulse Biosciences, Inc. Updates Investor Presentation

    On November 13, 2025, Pulse Biosciences, Inc. released an updated investor presentation highlighting product development progress. Key Highlights: New details on nPulse Vybrance Percutaneous Electrode.Progress updates on nPulse Cardiac Clamp and Catheter.Presentation to be used in investor and analyst meetings.Available on the company's website for public access.Original SEC Filing: PULSE BIOSCIENCES, INC. [ PLSE ] - 8-K - Nov. 13, 2025DisclaimerThis is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

    TradingView·
    US
    PLSE
    0.00%
    TradingView·
    US
    PLSE
    0.00%

    Pulse Biosciences Q3 2025 Earnings Call Highlights

    Pulse Biosciences Inc. held its Q3 2025 earnings call, highlighting mixed sentiments among stakeholders. The company reported progress in clinical trials and regulatory approvals, with initial revenues of $86,000 from product sales. However, financial challenges were evident, with a GAAP net loss increasing to $19.4 million and cash usage rising to $13 million. The nPulse Vybrance system is gaining traction, and the company is focused on advancing clinical trials and expanding market access. Overall, while there are promising developments, financial pressures remain a concern for the company.

    Tip Ranks·
    US
    PLSE
    0.00%
    Tip Ranks·
    US
    PLSE
    0.00%
    © 2025 Longbridge｜Disclaimer